NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Fortrea Holdings Inc. ("Fortrea Holdings Inc." or the "Company") (NASDAQ: FTRE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Fortrea Holdings Inc. investors who were adversely affected by alleged securities fraud between July 3, 2023 and February 28, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/psl ...

Core Viewpoint - Fortrea Holdings Inc. is facing a class action lawsuit due to alleged misleading statements and failure to disclose material adverse facts regarding its business performance and financial prospects during the class period from July 3, 2023, to February 28, 2025 [1][5]. Financial Performance - On March 3, 2025, Fortrea announced its financial results for the fourth quarter and full year 2024, reporting an adjusted EBITDA of $202.5 million, which was below the previously announced guidance of $220 million to $240 million [4]. - The company reported full year revenue of $2.696 billion, missing the guidance of $2.7 billion to $2.725 billion [4]. - For the full year 2025, Fortrea projected revenues between $2.450 billion and $2.550 billion and adjusted EBITDA in the range of $170 million to $200 million, indicating a decline from previous expectations [4]. Stock Price Movements - Following a downgrade by Jefferies on September 25, 2024, Fortrea's stock price fell by $2.73, or 12.3%, closing at $19.48 per share [2]. - On December 6, 2024, after Baird Equity Research expressed concerns about the company's performance, the stock price dropped by $1.90, or 8.1%, to close at $21.67 per share [3]. - After the disappointing financial results announcement on March 3, 2025, Fortrea shares fell by $3.47, or 25.1%, closing at $10.38 per share [4]. Allegations in the Lawsuit - The class action lawsuit alleges that Fortrea made materially false and misleading statements regarding its business model and financial projections, including overestimating revenue contributions from pre-spin projects and overstating cost savings from exiting transition services agreements [5]. - The lawsuit claims that the company's previously announced EBITDA targets for 2025 were inflated and that the viability of its post-spin business model was overstated [5].

Core Viewpoint - A lawsuit has been filed against Fortrea Holdings Inc. and its senior executives for potential violations of federal securities laws, alleging that the company overstated cost savings and revenue projections related to its transition services agreements with Labcorp [1][4]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled Deslande v. Fortrea Holdings Inc., et al., No. 1:25-cv-04630, and investors have until August 1, 2025, to seek lead plaintiff status [2]. - The claims are based on Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors who purchased Fortrea securities [2]. Group 2: Company Background - Fortrea is a global contract research organization that was spun off from Labcorp Holdings Inc. in June 2023, becoming a standalone publicly traded company [3]. - As part of the spin-off, Fortrea entered into transition services agreements (TSAs) with Labcorp, agreeing to pay for certain transitional services over a specified period [3]. Group 3: Allegations and Stock Performance - Allegations state that Fortrea exaggerated the cost savings and margin improvements expected from exiting the TSAs, as well as the revenue from pre-spin projects [4]. - Following a report from Jefferies on September 25, 2024, which indicated that the anticipated cost savings were not as significant as claimed, Fortrea's stock fell by $2.73, or over 12%, from $22.21 to $19.48 per share [5]. - On March 3, 2025, Fortrea announced disappointing Q4 and full-year 2024 results, leading to a further decline in stock price by $3.47, or over 25%, from $13.85 to $10.38 per share [6].

NEW YORK, June 16, 2025 /PRNewswire/ --The Gross Law Firm issues the following notice to shareholders of Fortrea Holdings Inc. (NASDAQ: FTRE).Shareholders who purchased shares of FTRE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/fortrea-holdings-inc-loss-submission-form/?id=152955&from=4CLASS PERIOD: July 3, 202 ...

Core Viewpoint - Fortrea Holdings Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding its financial performance and business model following its spin-off from Labcorp Holdings Inc. [1][3] Company Overview - Fortrea is a global clinical research organization (CRO) that provides development solutions for biopharmaceutical products and medical devices [2]. - The company was spun off from Labcorp in June 2023, with ongoing long-term projects at the time of the spin-off [2]. Allegations of the Lawsuit - The lawsuit claims that Fortrea overestimated revenue contributions from pre-spin projects, overstated cost savings from exiting transition services agreements (TSAs), and inflated its EBITDA targets for 2025 [3]. - Specific allegations include: - Overestimation of revenue from pre-spin projects [3]. - Overstatement of cost savings from exiting TSAs [3]. - Inflated EBITDA targets for 2025 [3]. - Overstated viability of Fortrea's post-spin business model [3]. Impact of Analyst Reports - On September 25, 2024, Jefferies downgraded Fortrea from buy to hold, citing weaknesses in its business model and a lack of material cost savings from exiting TSAs, leading to a stock price drop of over 12% [4]. - On December 6, 2024, Baird Equity Research downgraded Fortrea to neutral, resulting in an 8% decline in stock price after the company canceled two scheduled conferences [5]. Financial Performance Disclosure - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA projections for 2025 were not aligned with prior expectations, revealing that pre-spin projects were underperforming and negatively impacting financial performance [6]. - Following this announcement, Fortrea's stock price fell by more than 25% [6].

Core Viewpoint - A class action has been filed against Fortrea Holdings, Inc. for allegedly misleading investors regarding the progress of its pre-spin projects and financial expectations following its spin-off from Labcorp [1][2][4]. Group 1: Company Background - Fortrea Holdings, Inc. is a global contract research organization (CRO) that provides development solutions for biopharmaceutical products and medical devices [1]. - The company was spun off from Labcorp Holdings Inc. in June 2023 and entered into transition services agreements (TSAs) with Labcorp for various support services [2]. Group 2: Financial Performance - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA projections for 2025 were not meeting prior expectations, indicating that pre-spin projects were underperforming [3]. - The company reported that its pre-spin projects were "late in their life cycle" and had lower revenue and profitability than anticipated for 2025, leading to a significant stock price drop of 25.05% to $10.38 per share [3]. Group 3: Allegations and Misstatements - The complaint alleges that Fortrea overestimated the revenue contributions from pre-spin projects and overstated potential cost savings from exiting TSAs, inflating its EBITDA targets for 2025 [4]. - It is claimed that the viability of Fortrea's post-spin business model and financial prospects were also overstated during the class period [4].

Core Viewpoint - Fortrea Holdings Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding its financial performance and business model following its spin-off from Labcorp Holdings Inc. [1][3] Company Overview - Fortrea Holdings Inc. is a global clinical research organization (CRO) that provides biopharmaceutical product and medical device development solutions to various customers [2]. - The company was spun off from Labcorp Holdings Inc. in June 2023, with ongoing long-term projects at the time of the spin-off [2]. Allegations of the Lawsuit - The lawsuit alleges that Fortrea overestimated revenue contributions from pre-spin projects, overstated cost savings from exiting transition services agreements (TSAs), and inflated its EBITDA targets for 2025 [3]. - Specific claims include that Fortrea's business model viability and financial prospects were overstated, leading to significant stock price declines following negative reports from analysts [3][4][5]. Stock Performance and Analyst Reports - On September 25, 2024, Jefferies downgraded Fortrea from buy to hold, citing weaknesses in its business model, resulting in a stock price drop of over 12% [4]. - Following the cancellation of two scheduled conferences, Baird Equity Research downgraded Fortrea to neutral from outperform on December 6, 2024, leading to an additional stock price decline of over 8% [5]. - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA projections for 2025 were not aligned with prior expectations, causing a stock price drop of more than 25% [6]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Fortrea securities during the class period to seek appointment as lead plaintiff in the lawsuit [7]. - The lead plaintiff represents the interests of all class members and can select a law firm for litigation [8].

NEW YORK, June 14, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Fortrea Holdings Inc. (NASDAQ: FTRE) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Fortrea you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/fortrea-holdings-inc-class-action-lawsuit. Investors have until August 1, 2025, to ask th ...

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Fortrea Holdings Inc. ("Fortrea Holdings Inc." or the "Company") (NASDAQ: FTRE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Fortrea Holdings Inc. investors who were adversely affected by alleged securities fraud between July 3, 2023 and February 28, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/psl ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Fortrea Holdings, Inc. securities during the specified class period of the upcoming lead plaintiff deadline on August 1, 2025, and the potential for compensation without out-of-pocket costs [1][2]. Group 1: Class Action Details - The class action lawsuit has been filed against Fortrea Holdings, alleging that the company made false and misleading statements regarding its revenue projections and cost savings, which inflated its EBITDA targets for 2025 [4]. - Investors who purchased Fortrea securities between July 3, 2023, and February 28, 2025, may be eligible for compensation [1][4]. - A lead plaintiff must file a motion with the court by August 1, 2025, to represent other class members in the litigation [2]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise in this area [3].